EIF3A and ovarian carcinoma: Tumia R et al. also reported that high eIF3a expression increases radiotherapy and chemotherapy responses in patients with breast, gastric, lung, and ovarian cancer (Tumia et al., 2020), further suggesting that eIF3a may affect patient responses to treatments.